Reprogramming of Glioblastoma-Immune Crosstalk to Overcome Immunotherapy Failure 2258791
Glioblastoma multiforme (GBM) is a lethal brain cancer with a median survival of less than a year. Immunotherapies, such as immune checkpoint blockade (ICB), represent promising treatment options but still face challenges due to tumor resilience. Understanding how the brain and tumor environment shape immune resp...